Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Drug labeling and off-label use

In one sentence

Off-label use means a clinician uses an approved drug outside its approved labeling, while the evidence for that particular use must be assessed separately.

The intuition

A tool can have a well-tested use printed on its box, while someone proposes another use. The printed instructions tell you where the manufacturer and regulator have established a specific basis for use. A different use needs its own reasoning and evidence.

A medicine is more consequential than a household tool. This analogy explains the boundary; it cannot tell you whether a proposed off-label treatment is sensible.

How it works

The Food and Drug Administration (FDA) approves a medicine for specified uses based on a review of its benefits and risks. The prescribing information, often called the label, describes indications, dosing, contraindications, warnings and supporting studies.

An indication is the disease or condition and treatment context in which a drug is approved. In oncology, labeling may also specify a biomarker, prior treatments, a disease stage or a combination partner. Finding the drug's name on an approval page is only the beginning of a match.

Off-label use can involve a different disease, dose, route or other use outside approved labeling. Clinicians may generally prescribe approved drugs off label when they judge it appropriate. FDA has not established safety and effectiveness for that unapproved use merely because the drug has an approval elsewhere.

Evidence and labeling are related but distinct. Some off-label uses have substantial evidence and appear in clinical guidance. Others are speculative. “Off label” does not tell you which category you are in. Nor does it guarantee insurance coverage or access through a particular institution.

A drug never approved for any use is investigational, rather than simply off label. Obtaining it involves a different pathway, such as a clinical trial or expanded access.

Why it matters in cancer

A gene alteration and a drug targeting that gene's protein do not, together, establish that the drug helps this tumor. Ask whether the relevant alteration changes protein function, whether the drug reaches the target, and whether clinical evidence matches the disease and setting.

Similarly, evidence in metastatic disease does not automatically establish prevention of recurrence after surgery. The proposed goal and acceptable risk may be different.

Worked example

In a fictional report, Drug A is approved for advanced Cancer X with Alteration Y. The report names Drug A for a person with early Cancer Z and a different alteration in the same gene. The drug is real and approved, but the reported match crosses several evidence gaps. An oncology review must assess the actual variant, cancer, setting and alternatives.

Common confusions

  • A drug's approval is not approval of every molecular match a report proposes.
  • Off-label prescribing is not proof that the use works, and it is not the same as expanded access.
  • Insurance authorization answers a payment question, rather than establishing a treatment's effectiveness.
  • A label change can alter the regulatory status of a use. Check the current prescribing information.

Sources and scope

U.S. source check: October 9, 2026. The drug example is fictional. This page explains categories, not the suitability of an individual prescription. Expert and learner review remain pending.

Used in